GSK 561679A CAS 885220-61-1

Pwodwi Deskripsyon:

Non pwodwi: GSK 561679A CAS NON: 885220-61-1

 

Sinonim:

3-(4-Methoxy-2-methylphenyl) -2,5-dimethyl-N-[(1S) -1-(3-methyl-1,2,4-oxadiazol-5-yl) propyzolo[1,5-a]pirimidin-7-amine; Verucerfont;

CPD1230;

GSK561679;

 

Chimik & Pwopriyete fizik:

Aparans: Poud

Assay: ≥99.0%

Dansite: 1.29

PKa: 4.78±0.40 (predi)

 

Verucerfont (GSK-561,679) se yon dwog devlope pa GlaxoSmithline ki aji kom yon corticotropin lage resepte omon 1 (CRF1) antagonist. Corticotropin-divilge fakte (CRF), li te ye tou kom corticotropin-divilge omon, se yon omon peptide andojene ki se lage nan repons a dives deklannche tankou estres kwonik, ak aktive de corticotropin-lage resepte omon CRF1 ak CRF2. Sa a deklannche lage a nan corticotropin (ACTH), yon lot monn ki se ki patisipe nan repons lan fizyolojik nan estres.

Verucerfont blok resepte a CRH-1, e konsa réduit ACTH lage apre estres kwonik. Li se anba envestigasyon kom yon tretman potansyel pou alkol, tankou estres kwonik se souvan yon fakte nan tou de devlopman nan alkol ak rplonje nan rekipere alkol. Li te montre rezilta pwomet nan syans bet men li pa te teste nan moun.

 

Si ou enterese nan pwodwi nou yo oswa ou gen nenpot kesyon, tanpri santi yo lib yo kontakte nou!

 

Pwodwi anba patant yo ofri pou R & D rezon selman. Sepandan, denye responsablite a bay manti selman ak achte a.

Baj popilè: gsk 561679a cas 885220-61-1, manifaktire, founise, faktori, achte, nan stock

• On: 2 - [(5-kloro-2 - {[3-metil-1- (1-metiletil) -1H-pirazol-5-il] amino} -4-piridinil) amino] -N (metiloksi) benzamid CAS 1224887- 10-8
• Pwochen: Nazartinib CAS 1508250-71-2